Cataract is the clouding of the clear lens of the eye, where patients often find difficulties in sight, through the cloudy lenses, like looking through a frosty or fogged-up window. Some of the major cataract types include nuclear cataract, cortical cataract, posterior subcapsular cataract, and congenital cataract. The clumps of protein reduce the sharpness of the image reaching the retina. With time, the cloudy area in the lens becomes larger, seeing becomes more difficult, and vision becomes blurrier.
In most of the adult population, the disease becomes more prominent after the age of 40. Most of the time, the patient opts for cataract surgery. Companies are identifying new high-tech intraocular lens (IOL). With that in the development of therapeutics, the focus is on the development of molecules, to delay or prevent the formation of cataracts, with heat shock proteins, also known as alpha crystalline, which prevents misfolded proteins from aggregating in the lens of the eye.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors that have pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence